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A B S T R A C T   
In recent years, reactive species-based cancer therapies have attracted tremendous attention due to their 
simplicity, controllability, and effectiveness. Herein, we overviewed the state-of-art advance for photo-controlled 
generation of highly reactive radical species with nanomaterials for cancer therapy. First, we summarized the 
most widely explored reactive species, such as singlet oxygen, superoxide radical anion (O2●-), nitric oxide (●NO), 
carbon monoxide, alkyl radicals, and their corresponding secondary reactive species generated by interaction 
with other biological molecules. Then, we discussed the generating mechanisms of these highly reactive species 
stimulated by light irradiation, followed by their anticancer effect, and the synergetic principles with other 
therapeutic modalities. This review might unveil the advantages of reactive species-based therapeutic method-
ology and encourage the pre-clinical exploration of reactive species-mediated cancer treatments.   
1. Introduction 
Reactive species are necessary regulatory substances in various 
physiological functions [1,2]. As the most abundant components in or-
ganisms, the common nonmetal reactive species are generally based on 
oxygen, nitrogen, carbon, sulfur, etc [3–5]. Reactive species include a 
collective term of non-radical molecular forms (hydrogen peroxide 
(H2O2), CO, etc.) and the radical forms. Radicals refer to those atoms, 
ions, or molecules that contain unpaired electrons in the outermost 
electron orbitals, such as alkyl radical [6], nitric oxide (●NO) [7,8], 
peroxynitrite anion (ONOO− ) [9], hydroxyl radical (●OH) [10], chlorine 
radical (●Cl) [11] and superoxide radical anion (O2●-) [12]. These 
reactive species generally possess a short lifetime due to their high 
reactivity [13,14]. Low concentrations of reactive species exhibit 
beneficial effects in immune response and maintenance of redox ho-
meostasis and normal metabolisms of the cells [15–17]. In contrast, 
abnormal levels of reactive species can also lead to oxidative stress and 
even cell death by irreversibly damaging biofunctional macromolecules 
(nucleic acid, lipids, and proteins) [18,19]. The human body has an 
antioxidant defense system, comprising some small-molecule antioxi-
dants (e.g. Vitamin C and glutathione) and antioxidant enzymes 
(superoxide dismutases, catalase, glutathione peroxidases, peroxir-
edoxins, etc.) [20–22]. These antioxidants can abolish reactive 
species-induced oxidative stress to maintain the redox balance of the 
biological system [23]. 
Accumulated evidence has indicated that cancer cells possessed a 
high level of reactive species [24]. To keep the redox balance, most 
cancer cells have to generate more endogenous antioxidants [25]. The 
flexible alteration ability of redox status reduced the therapeutic effect 
of chemotherapy and radiotherapy on malignant tumor cells. Interest-
ingly, some experimental results suggested that reactive species could 
exhibit higher damaging effects to cancer cells than normal cells [26]. 
The preferential inhibition outcome might be attributed to the direct 
suppression of reactive species to endogenous antioxidants in cancer 
cells. Despite reactive species-based nanomedicine have intrinsic ad-
vantages, reactive species-based cancer therapy is restricted by several 
limitations: (1) oxygen dependence limited the therapeutic effects to 
hypoxic tumors; (2) the short absorption wavelength of photo-
activatable nanogenerators kept traditional reactive species-based 
nanoplatform from eliminating deep-seated tumors; (3) undesirable 
side effects derived from the nonspecific distribution of nanogenerators 
remain an issue. Regarding these concerns, researchers have been 
devoted to designing and creating theranostic platforms derived from 
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PTT Photothermal therapy 
NMOFs Nanoscale metal-organic frameworks 
ACQ Aggregation caused quenching 
AIE Aggregation-induced emission 
FRET Förster resonance energy transfer 
NIR Near-infrared 
CONs Covalent organic nanosheets 
EPR Enhanced permeability and retention 
DOX Doxorubicin 
UCNPs Upconversion nanoparticles 
TPZ Tirapazamine 
OVA Ovalbumin 
AuNCs Au nanocages 
PDT Photodynamic therapy 
PSs Photosensitizers 
POP Porous organic polymer 
SPNs Semiconducting polymer nanoparticles 
CA-IX carbonic anhydrase IX 
P-gp P-glycoprotein 
PTX Paclitaxel 
iNOS ●NO synthase 
DTX Docetaxel 
BSA Bovine serum albumin 
Hb Hemoglobin 
PCM Phase change material 
AIPH 2,2′-azobis[2-(2-imidazolin-2-yl)propane]dihydrochloride  
Scheme 1. Schematic illustration of the photoactivatable nanogenerators of reactive species including reactive oxygen, reactive nitrogen, and reactive carbon 
species for cancer therapy. 
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reactive species-based monotherapy or the featured synergistic therapy 
with other therapeutic strategies. 
The formation of reactive species in cells can originate from internal 
and external stimuli. The internal stimuli are specifically derived from 
some metabolic processes [27–32], or pathological conditions [33]. The 
external triggers are mainly starting from a range of physicochemical or 
biochemical reactions induced by reactive species generators. Growing 
bodies of the experimental data indicated that reactive species genera-
tors activated by light irradiation are excellent therapeutic candidates 
due to their noninvasiveness and spatiotemporally controllable profile 
in biomedical applications [34]. In this review, we first summarized the 
recent advances of photo-activatable nanogenerators for reactive species 
including reactive oxygen species, reactive nitrogen species, and reac-
tive carbon species (Scheme 1). We then discussed the principles for the 
design of photoactivatable nanoplatforms and their application for 
cancer therapy. We finally provided our perspectives for improving the 
therapeutic effect and promoting the clinical translation of the photo-
activatable nanoparticles. 
2. Reactive oxygen species-based antitumor therapy 
Reactive oxygen species (ROS) is composed of reactive radicals or 
non-radical molecules evolved from oxygen atoms. It is a collective term 
including singlet oxygen (1O2), superoxide radical anion (O2●-), hydroxyl 
radical (●OH), hydrogen peroxide (H2O2) [35]. ROS can destroy tumor 
cells through multifactorial mechanisms, including oxidizing the bio-
logical macromolecules, destroying angiogenesis to cut off the supply of 
nutrients to tumor cells [36,37]. Typically, five therapeutic strategies 
including radiation therapy [38–41], chemodynamic therapy [42–46], 
sonodynamic therapy [47–50], bioreductive chemotherapeutics (e.g., 
tirapazamine, TPZ) [51–54], and photodynamic therapy (PDT) [55–62] 
can generate ROS. Among all these approaches, PDT-based cancer 
therapies have been extensively exploited. 
PDT can be generally classified into oxygen-independent type-I and 
oxygen-dependent type-II mechanisms. The type-II PDT procedure can 
transform the photon energy to the photosensitizers (PSs) by exciting the 
PSs from the ground state to the singlet state. The excited singlet state 
PSs can further be converted to an excited triplet state through the 
intersystem crossing process. The excited triplet state PSs eventually 
transfer the photo energy to the molecular oxygen for generating singlet 
oxygen (1O2). In contrast, the type-I PDT can generate superoxide 
radical anions and hydrogen peroxide without the involvement of mo-
lecular oxygen (Fig. 1). The occurrence ratio of the two types of PDT is 
determined by the types of PSs and the concentration of the environment 
oxygen [63]. Furthermore, PDT can induce both apoptotic and necrotic 
death of the tumor cells. Notably, the dying tumor cells crack the plasma 
membrane and spill out the cytosolic constituents for provoking the 
inflammatory response, which can activate the protective immune 
response and suppress tumor growth via recruiting the 
tumor-infiltrating cytotoxic T lymphocytes [64]. In this section, we 
mainly discuss the advance of PDT-triggered reactive species generation 
with the nanogenerators. 
2.1. Photoactivatable nanoparticles for Type-II PDT of cancer 
Given the successful application of hematoporphyrin for PDT, 
extensive efforts have been devoted to designing various PSs and 
exploring their biomedical application. Up to date, both inorganic and 
organic nanomaterials have been exploited for PDT. The inorganic 
nanomaterials display superior colloidal stability in the physiological 
milieu [65–70]. The organic PSs harbor the special merits of good 
biocompatibility and biodegradability. Various organic 
nanomaterial-based PSs, such as porphyrin [71–75], boron dipyrrome-
thene (BODIPY) [76–78], cyanine dyes [79–82], aggregation-induced 
emission (AIE) molecules [83–90], have attracted considerable 
attention. 
The hydrophobic properties lead to the aggregation tendency of most 
PSs with π-π stacking structures, which heavily restricted the biomedical 
application of common PSs molecules. Thanks to the molecular assem-
bly strategies and the discovery of various carriers, these insoluble 
molecules could be prepared as multifunctional nanotherapeutic nano-
platforms. For instance, Yan et al. constructed a novel type of nano- 
photosensitize via coordination reaction between metal-binding pep-
tides, Zn2+ ions, and PS with multiple weak interactions using a multi-
component self-assembly strategy (Fig. 2a) [91]. The obtained 
self-assembled nano-phototherapeutics exhibited unique advantages 
including uniform size distribution, high PS loading efficiency, robust 
colloidal stability in physiological solution, and prolonged blood circu-
lation time in blood. Unsurprisingly, the self-assembled nano--
phototherapeutic displayed quenched photoactivity due to aggregation 
of PS in physiological conditions. In contrast, their photoactivity was 
restored inside the tumor cells by responding to acidic pH and elevated 
glutathione (GSH) expression, which endowed the nanoplatform with 
tumor-specific and highly efficient PDT of cancer. The self-assembly 
strategy could efficiently solve the solubility problem of PSs molecules 
with conjugated structures by forming nanoparticles. 
To acquire a favorable therapeutic effect, the nanoplatform should 
facilitate PSs drugs dwell in the tumor sites. Strategies that empower the 
nanoplatform with high accumulation and long-term retention at the 
tumor sites is worthy of being investigated. The solid tumor is of an 
acidic microenvironment due to glycolysis of the tumor cells. To take the 
advantage of the acidic tumor microenvironment, Pu et al. prepared a 
Fig. 1. The mechanisms of type-I and type-II PDT of cancer (R represents the substrate participating in the type-I photochemical reactions, ISC: intersystem crossing).  
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Fig. 2. (a) A schematic diagram of preparing supramolecular metallo-nanodrugs by the coordination of peptide, PSs, and Zn2+. Reprinted with permission [91]. 
Copyright 2018, American Chemical Society. (b) The transformation of peptide-porphyrin nanoparticles to peptide-porphyrin nanofibers activated by acid and the 
PDT application after intravenous injection. Reprinted with permission [92]. Copyright 2020, Wiley-VCH. (c) The formation of FHP photoactive nanostructure for 
NIRF imaging-guided PDT. Reprinted with permission [93]. Copyright 2020, Wiley-VCH. (d) The molecule structure of RDM-BDP for mitochondria targeting PDT. 
Reprinted with permission [94]. Copyright 2018, American Chemical Society. 
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kind of self-assembled acid-activated NPs with the peptide-porphyrin 
conjugates (Fig. 2b) [92]. The obtained peptide-porphyrin conjugate 
NPs could transform the spheroidal morphology into fibril nano-
structure by forming molecular hydrogen bonds under the acidic tumor 
microenvironment, thereby improving 1O2 generation efficiency and 
extending tumor accumulation of the nanoparticles. The 
peptide-porphyrin combined with morphology transformation function 
displayed excellent PDT performance. In this work, the acid-mediated 
morphology transformation strategy provided novel ways for elevating 
the accumulation of nanoparticles in the tumor regions. 
To enhance tumor accumulation of the nanomaterials in the deep 
tissues, the active targeting ligand can be used. Recently, Yin et al. 
prepared a perylene monoimide-based nanocluster with a size of about 
100 nm for fluorescence imaging-guided PDT of deep tumor (Fig. 2c) 
[93]. In their nanostructure system, the introduction of folate enabled 
the targeting capability to the tumor sites. The enzyme-triggered hy-
drolysis reduced the size of the nanostructure, eliciting the formation of 
ultrasmall NPs with a size of about 10 nm, which promised the suc-
cessful penetration of NPs into the deep tumor sites. After the 
hydrolysis-induced disassembly, the fluorescence emission of the 
nanocluster was recovered, and their 1O2 generation efficiency was also 
elevated for PDT. Featuring the enzyme-triggered size changes and the 
modified folate ligand in the structure, the nanoclusters achieved a deep 
tumor inhibition effect. 
To boost the therapeutic index, more strategies elevating the tumor 
accumulation amount of theranostic materials should be explored. 
Studies have found that some materials exhibited the nature tumor 
accumulation tendency due to the presence of delocalized positive 
charge in their molecular structures. Utilizing the special characteristics, 
Peng et al. designed a phototheranostic material-based RDM-BDP 
molecule with the mitochondria-targeting property (Fig. 2d). The smart 
structure with delocalized positive charges endowed RDM-BDP with the 
structure-inherent targeting function for enhanced tumor-targeting po-
tency. To further amplify the phototherapeutic outcome, they 
Fig. 3. (a) Synthetic procedure of Hf-DBP NMOF and the 1O2 generation under light illumination. Reprinted with permission [98]. Copyright 2014, American 
Chemical Society. (b) The structure of DBC-UiO and the photosensitization under light irradiation. Reprinted with permission [99]. Copyright 2015, American 
Chemical Society. (c) The formation schematic of UNM. Reprinted with permission [102]. Copyright 2017, American Chemical Society. (d) Structure schematic of 
HUC-PEG. Reprinted with permission [103]. Copyright 2020, Elsevier. (e) A schematic diagram of preparing TPE-PHO nanostructure and the substitution activated 
phototherapy mechanism. Reprinted with permission [101]. Copyright 2020, American Chemical Society. 
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introduced the Förster resonance energy transfer (FRET) mechanism 
into molecular designing. The FRET effect could optimize the photo-
chemical property of PSs by expanding their absorption regions, thus 
increasing their photon utilization efficiency, and promoting 1O2 gen-
eration. Assisted by the structure-inherent targeting function and FRET 
mechanism, the RDM-BDP-based nanoplatform exhibited notable 
phototoxicity to cancer cells and remarkable tumor inhibition effect in 
vivo upon 660 nm laser irradiation [94]. 
Apart from the above assembly strategies or direct dissolution by the 
organic solution to solve the hydrophobicity-induced aggregation 
problem of common PSs, the carriers have been intensively explored. 
The traditional polymer-carriers cannot completely avoid the aggrega-
tion state of hydrophobic molecules, which will partly counteract the 
photochemical property of photoactive materials. Thanks to the devel-
opment of materials chemistry, researchers demonstrated that nanoscale 
metal-organic frameworks (NMOFs) loaded with PSs molecules exhibi-
ted great advantage and potential. NMOFs as the vectors of porphyrin 
derivatives have been extensively employed for cancer therapy [95]. 
NMOFs with the periodic and ordered structures separate the porphyrin 
molecules from each other in the framework; thereby avoiding the ag-
gregation caused quenching (ACQ) effect of PSs [96,97]. Moreover, 
NMOFs are rich in porous structures, which provide passable diffusion 
channels for the generated reactive species and enhance the antitumor 
performance of PDT. For instance, Lin et al. fabricated a 
porphyrin-based NMOF (i.e., DBP-UiO) with plate morphology (Fig. 3a). 
PDT by DBP-UiO exhibited outstanding antitumor performance toward 
the drug-resistant tumors under 640 nm light irradiation with a dose of 
90 J cm− 2. The therapeutic efficacy of DBP-UiO could be attributed to 
the enhanced 1O2 generation efficiency induced by the heavy atom ef-
fect of Hf and ROS diffusion inside the MOF structures [98]. 
To improve the efficacy of PDT, Lin et al. further built a chlorin- 
based NMOF (DBC-UiO) with elevated photochemical reactivity and 
efficiently eliminated the colorectal tumors (Fig. 3b) [99]. The designed 
DBC-UiO possessed an elevated extinction coefficient in the 
lowest-energy Q band due to the successful reduction of porphyrin to 
chlorin [100,101], which endowed the amplified photon-harvesting 
capability for improved singlet oxygen generation efficiency. The inge-
nious DBC-UiO with optimized photophysical properties exhibited su-
perior PDT efficacy. 
Similar to NMOF, porous organic polymers (POP) integrating 
porphyrin were also exploited for PDT of cancer. For example, Xie et al. 
used the core-shell strategy to prepare a nanocomposite (UNM) by 
combining a metal-organic framework (UiO-66) with a porphyrin-based 
POP (Fig. 3c) [102]. Upon 450 nm light irradiation with a LED lamp, the 
porphyrin-based POP produced sufficient 1O2 to kill the tumor cells. 
Moreover, they demonstrated that chlorin-based POP displayed ampli-
fied 1O2 generation ability upon 671 nm laser irradiation (Fig. 3d) 
[103]. These porous materials-based phototheranostics remarkably 
inhibited tumor growth. 
ACQ phenomenon of the conventional PSs is a major obstacle for 
hydrophobic nanomaterial-based PDT. In past years, AIE molecules- 
based nanomaterials have been investigated as alternative photo-
therapeutic. The AIE molecules can emit fluorescence in an aggregate 
state and generate cytotoxic 1O2 under laser illumination [87]. Recently, 
Tang et al. designed a pyridinium-functionalized tetraphenylethylene 
AIE molecule (TPE-PHO) via host-guest interactions with water-soluble 
calixarene. The prepared complex structure formed the nanoplatform 
with supramolecular assembly (Fig. 3e) [101]. In normal conditions, the 
photoactivity of TPE-PHO was quenched for avoiding dark toxicity 
during blood circulation. In contrast, the TPE-PHO molecules were 
competitively replaced by 4,4′-benzidine dihydrochloride from the 
cavity of calixarene and the photoactivity of TPE-PHO molecules was 
restored, causing the generation of 1O2 upon white light illumination for 
PDT at the tumor sites. Moreover, the supramolecular assembly strategy 
in this work not only facilitates the nanometer form of PSs molecules but 
also provides the feasible methods for the application of materials with 
high dark cytotoxicity. Aiming at the hydrophobility problem of pho-
toactive agents, the AIE molecules exhibited great advantage by con-
verting enemies into friends. However, the short absorption wavelength 
and high dark cytotoxicity presented a formidable challenge to their 
further in vivo biomedical application. 
For oxygen-dependent type II PDT, the inherent tumor hypoxia 
limitation must be faced and conquered for superior phototherapeutic 
efficacy. To overcome the hypoxia drawbacks, four pathways have been 
studied in detail: (1) the direct method is supplying oxygen to the tumor 
sites utilizing the perfluorocarbon molecules or MnO2; (2) the employ-
ment of hypoxia-activated drugs (such as tirapazamine) can counteract 
the hypoxia drawback; (3) the way using the decomposition of H2O2 for 
supplying continuous O2 mediated by some metal-induced catalytic re-
actions have demonstrated their effectiveness in phototherapy of hyp-
oxic tumors; (4) the introduction of inhibitors towards hypoxia inducing 
factors can efficiently relieve the hypoxia stress. 
To demonstrate this, Chen et al. recently developed an iron- 
porphyrin MOF-based oxygen-supplying nanoplatform for PDT of can-
cer. Upon NIR laser irradiation, the nanoparticles were loaded with 
AuNPs, the latter can catalytic the glucose to generate H2O2 via glucose 
oxidase-like catalytic activity for starvation therapy. Subsequently, the 
produced H2O2 was decomposed to generate oxygen via photocatalysis 
reaction of Fe-porphyrin constructed MOF (Fig. 4a) [104]. Meanwhile, 
the porphyrin-based PSs could facilitate the generation of cytotoxic 1O2 
excited by the visible light emitted from the UCNPs. This novel system 
not only provided a continuous source of oxygen for PDT but also used 
the up-conversion mechanism to convert near-infrared light (980 nm) to 
visible light, which can solve the tissue-penetration problem of 
short-wavelength light. 
Similarly, Liu et al. used the oxidation etching strategy to prepare 
holey palladium nanosheets (namely H–Pd NSs) for overcoming the 
hypoxic tumor microenvironment and improving PDT performance 
(Fig. 4b) [105]. The palladium nanosheet without etching treatment was 
employed as a PTT agent. However, the etching decoration endowed the 
palladium nanosheets with the functionality of catalyzing the decom-
position of hydrogen peroxide to generate O2 (Fig. 4c). The generated O2 
was transferred into 1O2 photocatalyzed by H–Pd NSs upon 808 nm laser 
irradiation. This oxygen-supplying advantage endowed the nanosystems 
with similar photoinduced killing efficacy to 4T1 cells under hypoxia 
and normoxic conditions (Fig. 4d). The combinatory effect of photo-
thermal and PDT, the H–Pd NSs displayed satisfying therapeutic efficacy 
in vitro and in vivo, which have achieved a tumor inhibition rate of 
99.7%. 
In addition to the delicate nanoplatform to elevate the oxygen con-
centration at tumor sites, the direct inhibition of hypoxia-related 
cascade reactions for enhanced therapeutic effect has been investi-
gated. To relieve the side effects of PDT-induced hypoxic tumor micro-
environment, Pu et al. further designed a smart nanoplatform 
integrating a semi-conducting polymer-based PS and an antagonist of 
carbonic anhydrase IX (CA-IX) (Fig. 5a) [106]. The CA-IX inhibitor 
suppressed proliferation and metastasis of the tumor cells by dysregu-
lating the balance of both intracellular and extracellular pH (Fig. 5b). 
The integration of CA-IX inhibitor enhanced the targeting ability of the 
whole platform to CA-IX positive breast cancer cells. Upon 680 nm laser 
irradiation, the semiconducting polymer PS could efficiently produce 
1O2 for PDT. By combining the synergistic effect of PDT and anti-tumor 
metastasis mechanism, a remarkable therapeutic effect could be ob-
tained over monotherapy. 
The synergistic therapy could integrate the collective merits of 
employed multiple treatments and exhibited enhanced therapeutic ef-
fect. The introduction of hypoxia-responsive drug systems can efficiently 
inhibit the tumor cells in hypoxic conditions. For instance, Pu et al. 
conjugated a chemotherapy drug (IPM-Br) to the backbone of semi-
conducting polymer nanoparticles (SPNs) via a hypoxia-responsive 
linker (Fig. 5c) [107]. Upon 808 nm light illumination, the SPNs 
consumed O2 to generate 1O2 for PDT. The PDT intensified hypoxia 
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would cleave the hypoxia-sensitive linker and release the IPM-Br drug to 
crosslink the DNA macromolecules, thereby leading to cellular apoptosis 
(Fig. 5d). The synergistic PDT and chemotherapy exhibited 4.3-times 
higher tumor inhibition effectiveness than its chemotherapy process. 
2.2. Nanoparticles for Type-I PDT 
Just as a Chinese proverb says: “Better to divert rather than blocking 
and better to change rather than diverting”. This motto guides re-
searchers that the hypoxia targeting therapeutic modalities may be 
better than the direct oxygen-supplying methods, however, the 
designing of oxygen-independence nanomedicine platforms may possess 
the optimal therapeutic effect. Thanks to the repaid development of 
material synthetic chemistry tailed to biomedical application, re-
searchers demonstrated that some photoactivatable nanomaterials 
could perform type-I PDT in an oxygen-independent manner. These 
nanomaterials are of great potentials for PDT of hypoxic solid tumors. 
For example, Huang et al. prepared a novel nanostructure based on the 
self-assembled phthalocyanine molecules (NanoPcA) (Fig. 6a) [108]. 
NanoPcA with a unique structure design can avoid the ACQ phenome-
non and perform PDT with the type-I mechanism. 
Compared with organic nanomaterials-based PSs, metal-based PSs 
also exhibit remarkable photocytotoxicity in the tumor cells. Recently, 
Ruiz et al. constructed a PS complex by conjugating the cyclometallated 
Ir(III) to the coumarin molecules (Ir(III)–COUPY) (Fig. 6b) [109]. Ir(III)– 
COUPY was effectively endocytosed by HeLa cells and exhibited good 
biocompatibility in dark conditions. Upon blue or green light irradia-
tion, Ir(III)–COUPY induced a similar photocytotoxicity effect to HeLa 
cells under normoxic or hypoxic conditions. Mechanism studies indi-
cated that Ir (III)–COUPY caused cell death by generating superoxide 
Fig. 4. (a) A schematic diagram of the oxygen self-supplying UMOFs@Au NPs for enhanced PDT efficacy in vivo. Reprinted with permission [104]. Copyright 2020, 
American Chemical Society. (b) The preparation process of holey Pd NSs (H–Pd NSs). Reprinted with permission [105]. Copyright 2020, American Chemical Society. 
(c) The detection of the decomposition process of H2O2 into O2 by electron spin resonance spectra. Reprinted with permission [105]. Copyright 2020, American 
Chemical Society. (d) Viability of 4T1 cells treated with different conditions. Reprinted with permission [105]. Copyright 2020, American Chemical Society. 
Fig. 5. (a) The preparation of OPNi and (b) the mechanism of OPNi induced synergistic phototherapy. Reprinted with permission [106]. Copyright 2019, Wiley-VCH. 
(c) The preparation of SPNs photoactive nanomaterials for combined PDT/chemotherapy application. Reprinted with permission [107]. Copyright 2019, Wiley-VCH. 
(d) The release mechanism of IPM-Br for chemotherapy. 
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radical anion after visible light irradiation by performing the type I PDT 
process under hypoxia conditions. The generated superoxide radical 
anion could be confirmed by the emitting green fluorescence of dihy-
drorhodamine 123 (a ROS indicator) in a cell-free-media and the 
increased luminescence of luminol in the test of a cell-based assay. It is 
presumed that the Ir(III)–COUPY conjugates selectively produced su-
peroxide radical anion via the possible mechanism of suppressing 
intramolecular charge recombination. This work excavated the 
biomedical potential of the cyclometalated Ir(III) complex and coumarin 
by exploring their cytotoxic O2●- generation mechanism. The special 
photochemical behavior could be used to treat hypoxia tumor cells. 
However, the shorter absorption wavelength of Ir(III)–COUPY conju-
gates limited their further biomedical application in vivo. 
The above PS nanoplatform designing all employed ROS-active 
motifs as the main photoresponsive group, the ROS-inert motifs could 
also be favorable photoactivatable agents by forming a special structure. 
For instance, Deng et al. constructed two kinds of COF nanomaterials 
(called COF-808 and COF-909) with the photo-inactivatable molecular 
monomer L-3C (Fig. 6c) and L-3N (Fig. 6d) as building units, respec-
tively [110]. The cross-linked COF-808 and COF-909 generated a large 
number of superoxide radical anions under 630 nm light irradiation. The 
generated superoxide radical anions subsequently reacted with the H2O 
molecule to form the hydroxyl species. PDT study in vitro showed that 
COF-909 killed more than 80% of the tumor cells at a concentration as 
low as 50 μg/mL. The antitumor studies demonstrated that COF-909 
inhibited over 90% of tumor growth compared with that of the un-
treated control group, indicating the promising potential of COF-909 for 
type-I PDT. However, the clinical translation of these COF structures was 
restricted by their poor physiological stability. 
Besides the traditional nanoparticle mode-based phototherapy, the 
direct small organic molecules have also been explored as efficient PDT 
agents. For instance, Peng et al. developed a superoxide radical anion 
generator (ENBS-B) based on the benzophenothiazine compounds, 
which could be activated by NIR light (Fig. 6e) [111]. Upon 660 nm 
laser irradiation, the obtained ENBS-B could produce sufficient O2●- 
under light irradiation in a hypoxic environment through the type-I 
photochemical reaction for PDT (2% O2). The intracellular uptake 
amount of ENBS-B was about 87-times higher than the control groups 
due to the targeting effect of biotin ligands. The generated O2●- species 
can destroy the intracellular lysosomes and induced tumor cell apoptosis 
while participating in SOD-mediated reactions to form H2O2 and highly 
toxic ●OH. ENBS-B specifically targeted the tumor tissues and efficiently 
inhibited tumor growth by low-dose laser irradiation when adminis-
trated by intravenous injection. 
To improve the photochemical property of the nanogenerators, Peng 
et al. further developed another nanophototherapeutic generating su-
peroxide radical anion (O2●-) for type-I PDT (Fig. 6f) [12]. The 
photon-absorption capacity of ENBOS in the NIR region was signifi-
cantly amplified via the FRET mechanism. ENBOS could be activated by 
laser irradiation at low photodensity. Remarkably, ENBOS displayed 
excellent “structure inherent targeting” ability. The signal-to-noise ratio 
of the tumor and surrounding tissues reach 25.2 when administrated by 
intravenous injection, indicating the excellent tumor targeting ability of 
ENBOS. Furthermore, ENBOS effectively eliminated the hypoxic tumor 
owing to the structural intrinsic localization function, strong photon 
absorption capacity, and oxygen-independence characteristic. 
To alleviate the hypoxia burden of tumor cells and acquire more 
right to use the existing oxygen in the tumor cell, Peng et al. further 
designed a superoxide radical anion (O2●-) generator (called SORgen-
TAM), which was able to reverse the hypoxia-induced therapeutic 
resistance by acting on mitochondrial respiration (Fig. 6g) [112]. Spe-
cifically, the tamoxifen molecule in the nanotherapeutic structure 
affected the normal process of mitochondrial respiration, reduced the 
hypoxic pressure of tumor cells by preventing O2 consumption in the 
tumor cells, and simultaneously down-regulated HIF-1 expression, 
thereby preventing the tumor cells from becoming hypoxic. The 
photosensitization studies demonstrated that the superoxide radical 
anion could transform into hydroxyl radical via a cascade of catalytic 
reactions. Moreover, the antitumor study suggested that SORgenTAM 
inhibited self-repair of the tumor cells by activating the AMPK meta-
bolism signaling pathway and enhanced the lethal effect to tumor cells. 
This study suggested that the SORgenTAM phototherapeutic platform 
could be tailored for treating deep-seated hypoxia tumors. 
2.3. Nanoparticles for combined Type I and II PDT 
Thanks to the richness and diversity of existing materials and the 
advance of synthetic chemistry, researchers have found that some 
phototherapeutic nanomaterials could simultaneously perform the O2- 
dependent and O2-independent PDT. For instance, Lin et al. developed a 
Ti-based NMOF (Ti-TBP) for combining Type-I and Type-II PDT process 
(Fig. 7a) [113]. Upon 650 nm laser irradiation, the Ti-TBP NMOF pro-
duced 1O2 and transferred electrons from the excited TBP* species to 
Ti4+-based secondary building units, generating TBP●+ ligands and Ti3+
centers, thereby promoting the generation of superoxide anions 
hydrogen peroxide and hydroxyl radicals. Thus the bifunctional Ti-TBP 
NMOF nanophototherapeutics-mediated PDT exhibited a superior anti-
cancer effect by generating four different types of ROS and efficiently 
inhibited the solid tumor growth (~98%) under 650 nm light 
irradiation. 
Fig. 6. (a) Molecular structure of PcA. (b) Molecular structure of the Ir(III)–COUPY conjugate. (c) The molecule structure of L-3C for constructing COF-808. (d) The 
molecule structure of L-3N for constructing COF-909. (e) Molecular structure of ENBS-B. (f) Molecular structure of cationic superoxide radical anion generator- 
ENBOS. (g) Molecular structure of SORgenTAM. 
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To improve the antitumor performance of the nano- 
phototherapeutic, Lin et al. further prepared a Zr-TBB NMOF by utiliz-
ing bacteriochlorophyll as the connecting unit and zirconium as the 
metal node (Fig. 7b) [98]. Under 740 nm laser irradiation, Zr-TBB 
NMOF triggered superoxide anions, hydrogen peroxide, hydrogen 
peroxide, and singlet oxygen generation through the type-I and type-II 
mechanisms, leading to a favorable PDT effect. The four kinds of reac-
tive oxygen species were verified by aminophenyl fluorescein assay and 
electron paramagnetic resonance measurement. In vivo studies showed 
that the Zr-TBB NMOF was of excellent antitumor efficacy in the mouse 
models of breast and colorectal cancer, with cure rates of 40% and 60%, 
respectively. 
In addition to NMOF, covalent organic porous nanostructures gained 
extensive attention in recent years due to their framework structures and 
tunable photochemical properties. For instance, Tian et al. prepared a 
heterogeneous covalent organic nanosheet (CON) with a donor-acceptor 
structure (Fig. 7c) [114]. Upon 635 nm laser irradiation, the porphyrin 
PS molecules in the nanosheet generated 1O2 for type-II PDT. Besides, 
the heterostructure of CONs provided efficient charge separating effi-
ciency to obtain long-lived electrons and holes. Electrons reduced O2 to 
form O2●-, and holes oxidized water to produce toxic ●OH to exert the 
type-I PDT process. The type-I PDT function significantly relieved the 
hypoxia-induced resistance to type-II PDT. The CONs displayed signifi-
cant tumor suppression effect by combining type I, type II PDT and PTT 
modality when administrated by intravenous injection. This work 
explored the photochemical mechanism of porphyrin-based CONs and 
expanded the biomedical application of indissoluble covalent organic 
nanomaterials. 
3. Reactive nitrogen species-mediated tumor suppression 
Reactive nitrogen species (RNS) contains nitric oxide (●NO) and a 
wide range of its metabolites, such as peroxynitrite anion (ONOO− ) [23, 
115–118]. As a biological regulatory molecule in the human body, ●NO 
plays crucial functions in various physiological and pathological pro-
cesses [7,8,119]. Therefore, ●NO is closely related to the occurrence and 
progression of many diseases including cancer [117]. Similar to reactive 
oxygen species, ●NO is a double-edged sword, and its biological effects 
are concentration-dependent [120]. For instance, ●NO can promote 
angiogenesis of the solid tumor at a concentration below 0.2 μmol. In 
contrast, ●NO caused poisoning effect in the blood at a concentration of 
●NO higher than 1 μmol [121]. When ●NO is maintained at a certain 
concentration (>1 μmol), it could inhibit tumor growth and eventually 
regressed tumor [122–124]. The main antitumor mechanisms of ●NO 
are as follows: (1) affecting the energy metabolism of cancer cells, which 
resulted in tumor suppression; (2) combining with reactive oxygen 
radicals (such as superoxide radical anion) in the cell to damage the 
skeleton structure of DNA by generating nitrogen/oxygen-based free 
radicals; (3) promoting macrophage activation to fight tumors, and 
inhibiting tumor metastasis by down-regulating the platelet aggrega-
tion; (4) inducing and activating the expression of tumor suppressor 
gene p53 for causing tumor cell apoptosis; and (5) reducing P-glyco-
protein (P-gp) expression levels against drug resistance. 
As a typical radical, ●NO is the source of all RNS in the biological 
systems [125]. ●NO possess high reactive activity in the presence of 
other radicals and exhibit oxidation or nitration potential to the local 
biomolecules. Therefore, precise cancer therapy can be achieved by 
controlling ●NO release at the lesion locations. Generally, there are four 
bonding strategies including R-O-NO, R-S-NO, R-N-NO (R represents 
alkyl group), and mental-NO for ●NO delivery [126]. The four bonding 
or coordination-based ●NO supplying nanotherapeutic platforms can 
achieve light irradiation-triggered ●NO release. The external light 
irradiation-induced photothermal effect can also induce a controlled 
release of ●NO. However, despite various nanomaterials that have been 
designed for ●NO-delivery, it remains a challenge to precisely deliver 
●NO to the tumor sites in a controlled release profile. 
●NO-based monotherapy application is relatively rare due to the 
concentration-dependent therapeutic effects of ●NO. However, NO- 
based combination therapy has been extensively studied. Current 
●NO-based treatment research mainly focuses on four pathways, 
including high concentration-induced cytotoxicity [127], as a chemo-
therapy sensitizer [128], as radiation therapy sensitizer [129], or as 
phototherapy sensitizer [120,122]. The ever-increasing antitumor 
research about the combination of ●NO therapy with various thera-
peutic strategies demonstrated the great significance of summarizing the 
related research works. In this section, the mechanism and advantages of 
synergistic therapy between ●NO therapy and other therapeutic mo-
dalities will be discussed for discovering innovative methods to cure 
Fig. 7. (a) Schematic structure of Ti-TBP NMOF enabling both types I and type II PDT. Reprinted with permission [113]. Copyright 2019, American Chemical 
Society. (b) Coordinated complexation of bacteriochlorin ligands and Zr4+ to obtain Zr-TBB NMOF for type I and type II PDT. Reprinted with permission [98]. 
Copyright 2020, American Chemical Society. (c) The mechanism schematic of porphyrin-based 2D CON for PTT and type I PDT. Reprinted with permission [114]. 
Copyright 2019, American Chemical Society. 
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cancer. 
The drug delivery rate for tumor clinical chemotherapy is low due to 
the limitation of physiological barriers, which lead to poor therapeutic 
outcomes and tumor metastasis. Studies have shown that a low dose of 
●NO can amplify the permeability and retention effects (EPR) of the 
nanoparticles. Moreover, ●NO has been extensively employed for 
sensitizing the tumor cells to chemotherapeutics, such as cisplatin, 
paclitaxel (PTX), and doxorubicin (DOX). For example, Kim et al. 
designed a polymer micelle formed by nitrobenzene and platinum pro-
drugs by conjugating with nitrobenzene molecules at both ends of the 
platinum prodrugs in the axial direction (Fig. 8a) [128]. The strong 
hydrophobic property of nitrobenzene improved the loading efficiency 
of Pt(IV) prodrugs when utilizing polymeric micelles as the carrier. The 
photo-cleavage of the nitro compound transformed the hydrophobic 
nitrobenzene into a hydrophilic phenol structure, which further 
increased the release efficiency of platinum (IV) prodrugs. This nano-
medicine platform utilizing ●NO donors for tuning ●NO release and 
boosting chemotherapy exhibited effective anticancer effects. However, 
the tissue penetration of the ultraviolet light is quite limited, which 
restricted the biomedical application of nitro benzene-based ●NO do-
nors in vivo. 
Similarly, ●NO can be used to amplify the chemosensitivity of PTX 
by the bonding method of R-S-NO. Li et al. constructed an antitumor 
nanoplatform (IPH–NO NPs) by utilizing the ●NO donor bonded human 
serum albumin as a drug carrier to support the photosensitizer (IR780) 
and PTX (Fig. 8b) [130]. IPH-NO NPs slowly released ●NO in the 
presence of glutathione (GSH), thus leading to elevated permeability of 
NPs to the tumor blood vessels and improved drug accumulation at the 
tumor sites. Moreover, the NIR light irradiation induced the rapid 
release of ●NO, which directly killed tumor cells, and inhibiting tumor 
metastasis. This nanoplatform exhibited improved tumor suppression 
effect and anti-metastasis effect by the synergistic therapy of ●NO 
therapy, photothermal therapy, and chemotherapy. 
Also, ●NO can be used to enlarge the chemosensitivity of DOX by co- 
delivery of ●NO donor (metal-NO coordination complex) and DOX drugs 
in one nanoplatform. Shen et al. designed a nanoplatform and proved 
the positive effect of ●NO on DOX-based chemotherapy (Fig. 8c) [131]. 
In this nanoplatform, chitosan was bonded on the surface of upconver-
sion nanoparticles (UCNPs) and then loading DOX and photoactivated 
●NO donor (Ruxin black salt, RBS) to obtain the nanospheres (UCNPs 
(DOX)@CS-RBS) (Fig. 8c). The UCNPs in the nanospheres effectively 
converted absorbed NIR photons into visible light, triggering the release 
of ●NO. The low pH in the lysosome promoted the release of DOX. They 
demonstrated that a small dose of ●NO acted as a P-gp-mediated ther-
apeutic agent against multidrug resistance (MDR), leading to the 
increased concentration of DOX in the cell. In the meantime, the high 
dose of ●NO and DOX synergistically killed cancer cells. The combina-
tion of DOX and high doses of ●NO exhibited an improved tumor pro-
liferation suppression effect. It has been defined that the multidrug 
resistance had severely limited the therapeutic effect of chemothera-
peutic. Therefore, the successful introduction of ●NO should be of great 
practical significance. 
In addition to combination with chemotherapy, ●NO has also been 
used to optimize the therapeutic effect of PDT on hypoxia tumors. For 
instance, Dong and Huang et al. synthesized a nano-PS based on the 
diketopyrrolopyrrole nucleus (DPP-NF) (Fig. 9a) [122]. They introduced 
a light-responsive ●NO donor (4-nitropyrrole) and pH-sensitive group 
(dimethylaminophenyl) into the structure of DPP-NF NPs (Fig. 9b). The 
DPP-NF NPs could be activated under weakly acidic conditions of ly-
sosomes (pH = 4.5–5.0) by forming protonated structure to generate 
ROS for PDT and enable the photothermal conversion function for PTT 
under laser irradiation. Moreover, upon 660 nm light illumination, the 
released ●NO was able to trigger tumor cell death by inducing DNA 
damage. The ●NO therapy could overcome the low efficiency of PDT 
modality to hypoxic tumors. Both in vitro and in vivo antitumor effects 
demonstrated that DPP-NF NPs are promising phototherapeutic 
nanoplatform. 
It is well known that PDT could suppress tumor growth by causing 
irreversible oxidative damages to the lipids, amino acids, and proteins. 
However, some recent evidence have shown that the concentration of 
●NO synthase (iNOS) was upregulated during the PDT process. The 
iNOS or ●NO donors generated ●NO could suppress the PDT-induced 
Fig. 8. (a) The structure schematic of the photoactive Pt(IV) prodrug. Reprinted with permission [128]. Copyright 2018, Royal Society of Chemistry. (b) Schematic 
illustration of the IPH-NO for enhanced antitumor therapy. Reprinted with permission [130]. Copyright 2019, Royal Society of Chemistry. (c) The release mechanism 
of UCNPs(DOX)@CS-RBS nanomaterials activated by light illumination and the acid. Reprinted with permission [131]. Copyright 2017, Royal Society of Chemistry. 
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photokilling effect to cancer cells via weakening the lipid peroxidation 
effect [121]. So the nanomaterials designing about combination of ●NO 
therapy and PDT need to consider more experimental variables to fully 
understand the function mechanism, thereby obtaining optimal PDT 
efficacy. 
●NO has also been used as an efficient photothermal therapy (PTT) 
sensitizing agent. Uneven heat distribution often leads to poor accuracy 
of treatment and side effects of burning normal tissues during the PTT 
process. Therefore, mild PTT is a considerable alternative and could be 
explored for antitumor research. Zhao and Gu constructed a nano-
composite based on the bismuth sulfide (Bi2S3) NPs and a ●NO donor 
(bis-N-nitroso compound, BNN). Under 808 nm light illumination, BNN 
released ●NO facilitated the even distribution of nanocomposite in solid 
tumors for mild PTT. Moreover, the exploration result indicated that the 
self-repair function of tumor cells was inhibited, thus achieving an 
excellent PTT effect [120]. The results suggested that ●NO could 
cooperate with PTT modality to suppress the growth of tumor cells. This 
work provided novel insight for avoiding the side effects of hypothermia 
therapy. 
Radiotherapy is commonly used for cancer treatment in the clinic. 
However, the therapeutic efficiency of radiotherapy is generally unsat-
isfactory, due to its low specificity, limited drug resistance, and side 
effects caused by high doses of radiation. Researchers have found that 
●NO can effectively sensitizer radiotherapy. For instance, Wang et al. 
Fig. 9. (a) Schematic illustration of DPP-NF NPs for multifunctional cancer therapy. Reprinted with permission [122]. Copyright 2018, Royal Society of Chemistry. 
(b) The release mechanism of ●NO from DPP-NF NPs. Reprinted with permission [122]. Copyright 2018, Royal Society of Chemistry. (c) The preparation of 
Ag2S@BSA-SNO for cancer therapy. Reprinted with permission [129]. Copyright 2020, Springer Nature. (d) The preparation process of m-PB-NO for antitumor 
therapy. Reprinted with permission [127]. Copyright 2019, Elsevier. (e) PA imaging-guided ●NO/photothermal combination therapy. Reprinted with permission 
[132]. Copyright 2019, Elsevier. (f) Molecule structure of photoNOD and rNOD. (g) PA imaging of photoNOD-1 and release of ●NO. 
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recently synthesized a controlled therapeutic platform by using bovine 
serum albumin (BSA) as a carrier of Ag2S quantum dots, ●NO donors 
(TBN), and ovalbumin (OVA) (Fig. 9c) [129]. The photothermal effect of 
the nanoplatform upon 808 nm light irradiation precisely triggered the 
release of ●NO, which optimized the radiotherapy effects of heavy 
metal-Ag and immunotherapy effect induced by OVA. The antitumor 
study in vivo showed that the survival rate of tumor-bearing mice 
reached 100% after the treatment of this multifunctional nanoplatform. 
Compared with the control group, the tumor volume of the 
●NO-combining treatment group was the smallest, indicating the 
radiotherapy sensitization effect of ●NO. 
In addition to the adjuvant function to other therapy modalities, 
●NO can directly improve tumor treatment efficacy at sufficient con-
centration. For example, Zhang and Feng have doped ●NO donor (so-
dium nitroprusside, SNP) into the mesoporous Prussian blue (m-PB) NPs 
to obtain m-PB-NO NPs, and then loading docetaxel (DTX) to construct 
the DTX@m-PB-NO platform (Fig. 9d) [127]. By adjusting the intensity 
and time of NIR light irradiation (808 nm), ●NO was released in a 
controlled manner. This system combined ●NO therapy, PTT, and 
chemotherapy to effectively inhibit tumor growth and metastasis. 
Similarly, Fan et al. used F127 to encapsulate semiconducting polymer 
and s-nitrosothiol group (SNAP) to form a theranostic platform (Fig. 9e) 
[132]. Upon 808 nm laser irradiation, the encapsulated semiconducting 
polymer converted light to heat energy for PTT treatment. The gener-
ated heat decomposed s-nitrosothiol to produce ●NO for cooperative 
treatment of ●NO and PTT. The combined treatment strategy inhibited 
the tumor growth up to a 77% percentage. The synergistic therapy by 
combining ●NO and PTT modality has great potential due to the 
favorable antitumor efficacy. 
Along with the therapeutic effect of ●NO, Chan et al. recently syn-
thesized a ●NO donor (photoNOD) for photoacoustic (PA) imaging by 
using aza-BODIPY as the backbone [133]. This NIR light provided 
enough energy to break the N-nitroso bonds, which helped BODIPY 
molecules to generate a strong PA signal under excitation, and the 
photophysical properties were also affected by the change of chemical 
structure. This NIR light-controlled property enabled the molecule to be 
an ideal ratiometric probe. After NIR irradiation, photoNOD-1 and 
photoNOD-2 released ●NO and generated aza-BODIPY (rNOD-1 or 
rNOD-2) (Fig. 9f). The conversion from electron-deficient N-nitroso 
bond to electron-rich N–H bond caused the absorbance redshift of the 
molecule. The irradiation of photoNOD and rNOD with two wavelengths 
of light led to the generation of two corresponding PA signals, and the 
generated ratio signals could detect the ratio of photoNOD and rNOD 
and non-invasively monitor the release of ●NO in living animal tissues. 
Compared with a fluorescence-based imaging modality, PA imaging of 
photoNOD offered a non-invasive and high-resolution imaging strategy 
to detect the ●NO release process without additional contrast agents 
(Fig. 9g). This work demonstrated that the ●NO-based reactive species 
can not only optimize the therapeutic effect of common cancer therapy 
but also play a part in the imaging field. The potential of ●NO for PA 
imaging will be beneficial for performing tunable and tumor-specific 
●NO delivery with the ●NO donors-containing nanomaterials. 
4. Carbon-containing reactive species for cancer therapy 
Carbon-containing reactive species are kinds of carbon-centric de-
rivatives. Herein, we mainly overviewed the advances of CO and alkyl 
radicals-based carbon-containing reactive species for cancer therapy 
[4]. 
4.1. CO-performed cancer therapy 
It is well known that the binding affinity of CO for hemoglobin (Hb) 
is 220-times higher than that of oxygen [134,135]. Therefore, CO can 
disrupt the oxygen-carrying capacity of Hb in the blood, thus causing 
poisoning effects. CO can also inhibit the function of mitochondria and 
induce autophagy of the cells. However, CO is a metabolite of endoge-
nous heme. As an endogenous signaling molecule, CO has a variety of 
biomedical functions, such as regulating blood pressure, reducing 
inflammation, sensitizing the tumor cells to chemotherapy, and dys-
functionalizing mitochondrial aerobic breathing energy supply [134]. 
Based on these functionalities, the study of CO as a therapeutic agent has 
received widespread attention [136,137]. However, to avoid the toxicity 
of CO, it is essential to deliver CO specifically to the tumor sites and 
release the payload on demand. Currently, various nanocarriers (such as 
polymers, ferric oxide, silica nanoparticles, Au nanocages (AuNCs), etc.) 
have been developed to support the CO donors (Ru carbonyl, Fe 
carbonyl, and Mn carbonyl). In this section, the potential application 
and mechanism of CO-based multifunctional nanomaterials for anti-
tumor therapy are summarized. 
Based on the special functionality, Zhang et al. used AuNCs to sup-
port CO donor-iron pentacarbonyl (Fe(CO)5) under anaerobic condi-
tions, avoiding leakage and oxidation during the blood circulation. The 
iron pentacarbonyl on the surface of Au nanocages could turn into iron 
oxide under aerobic conditions (Fig. 10a) [138]. Upon 808 nm laser 
irradiation, Au converted light to heat energy and promoted the 
decomposition of iron pentacarbonyl into CO and iron. The generated 
CO interfered with the respiration of mitochondrial, induced autophagy, 
and damaged the lysosome in cancer cells. Besides, the produced iron 
and the iron oxide degraded under the weak acidity of the lysosome and 
underwent Fenton reaction for producing cytotoxic hydroxyl radicals, 
which further destructed the autolysosomes, and improved the anti-
cancer performance. This study combined the CO therapy with hydroxyl 
radicals-induced oxidative damage demonstrated the potential of CO 
species for antitumor therapy. 
Apart from utilizing the influence of CO on the function of mito-
chondrial for tumor regressing, CO could also be employed to enhance 
the performance of chemotherapy. To overcome the resistance of 
chemotherapy, small molecule chemosensitizers are used to make tumor 
cells more sensitive to chemotherapeutics. Studies indicated that CO 
could act as a chemotherapy sensitizer and also exert the function of 
anti-inflammatory. For instance, Zhang et al. designed a multifunctional 
CO nanogenerator based on partially oxidized tin disulfide nanosheets 
(POS NSs) to inhibit tumor growth and suppress inflammatory response 
(Fig. 10b) [139]. POS NSs are modified with targeting 
ligand-functionalized polymers (PEG-cRGD) for improving their tumor 
specificity. POS NSs can efficiently load DOX to prepare PPOSD due to 
the large surface area and volume of NS. The resultant PPOSD could 
catalyze CO2 to generate CO upon 561 nm laser irradiation, and sensitize 
the tumor cells to DOX treatment. Moreover, the POS NS in PPOSD can 
induce hyperthermia effect upon laser irradiation for photothermal 
ablation of the tumor. The produced CO could reduce the inflammatory 
response caused by PTT. This study effectively explored the 
anti-inflammatory function of CO and uncovered its action mechanism. 
Similarly, Shen et al. developed the MCM@PEG–CO–DOX NPs by 
firstly oxidizing the ferrocene compound to obtain carbonized magnetic 
NPs (MC), and then modifying the surface of MC with iron-based MOF 
(MIL-100) and utilizing MIL-100 as a carrier for supporting the CO 
donor-Mn(CO)5Br and DOX (Fig. 10c) [140]. Upon 808 nm laser irra-
diation, MC produced photothermal effects for triggering CO and DOX 
release. The combination of CO with chemotherapy and PTT elicited an 
excellent tumor suppression effect. The study demonstrated the poten-
tial application of CO for improving chemo- and photothermal therapy 
of cancer. 
CO as the anti-inflammatory agent could precisely avoid the reverse 
effects (i.e., inflammation) of PTT. To verify the feasibility, Zhang et al. 
used defective tungsten oxide (WO3) nanosheets (DW NSs) to support 
carbon dioxide donor-bicarbonate (BC) and then modified their surface 
with polyethylene glycol (PEG) to make P@DW/BC nanosheets [141]. 
Upon 808 nm laser irradiation, the DW in P@DW/BC exerted PTT 
function and converted carbon dioxide (CO2) into CO via photocatalysis 
process. Combining the photothermal and anti-inflammation effects of 
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CO, the prepared nanosheets have exhibited excellent antitumor effects 
with low adverse side effects. 
Moreover, recent studies have indicated that CO could accelerate the 
oxygen consumption of mitochondrial, promoting a hypoxic environ-
ment for activating the hypoxia-activatable prodrug. For example, Yin 
et al. prepared a theranostic nanoplatform by utilizing m-PB NPs as 
carriers to support the tirapazamine (TPZ) and iron pentacarbonyl (Fe 
(CO)5, CO donor) (Fig. 10d) [137]. The modification of polyallylamine 
hydrochloride (PAH) and polyacrylic acid (PAA) on the surface pro-
longed the blood circulation of the nanoplatform and promoted its 
accumulation in tumor sites. After intravenous injection, the photo-
thermal effect of PB under 808 nm light irradiation induced the cleavage 
of the coordination bonds in Fe(CO)5, thus releasing CO. Subsequently, 
CO accelerated the aerobic respiration of mitochondria and increased 
the hypoxic extent of tumor cells. The hypoxic environment further 
activated the bioreductive chemotherapeutic TPZ, which can generate 
transient oxidative free radicals during the metabolism of reductase to 
combine with DNA, leading to DNA damage and subsequent cell death. 
CO-mediated activation of TPZ significantly enhanced the antitumor 
efficacy of TPZ-mediated chemotherapy. This pioneering study inge-
niously explored the influence of CO on the oxygen consumption of 
mitochondrial and broadened its biomedical application. 
Studies have found that the mechanism of multidrug resistance is 
related to the P-glycoprotein (P-gp)-mediated drug efflux of the cancer 
cell, and the function of P-gp highly depends on the binding of ATP 
[142]. There are various strategies to overcome P-gp-involved MDR: (1) 
using P-gp inhibitors to reduce nicotinamide adenine phosphate 
dinucleotide (NADPH) and adenosine triphosphate (ATP) to 
down-regulate P-gp expression. (2) designing anticancer drugs targeting 
mitochondria and using interfering RNA to silence P-gp expression. 
Studies have found that CO could reverse the drug resistance of 
chemotherapy by inactivating mitochondria and suppressing the func-
tion of P-gp. For example, Yin et al. reported the strategy of using CO for 
overcoming the MDR process [143]. They used mesoporous Prussian 
blue nanoparticles (PB NPs) as a carrier to support iron pentacarbonyl 
(Fe(CO)5) and DOX. Upon 808 nm laser irradiation, the Fe(CO)5 released 
CO via photothermal breakdown, resulting in mitochondrial metabolic 
failure. This process prevented the synthesis of ATP and inhibited 
ATP-dependent drug outflow, thus reversing drug resistance of 
MCF-7/ADR tumors. Besides, CO-mediated mitochondrial failure acti-
vated the apoptotic protein caspase 3, which further lead to the tumor 
cell apoptosis. 
4.2. Alkyl radical-mediated cancer inhibition 
ROS can inhibit the proliferation of the tumor cells by inducing 
oxidative damage to biomolecules (e.g., lipids, proteins, and DNA) and 
subcellular organelles (i.e., mitochondria). However, the generation of 
ROS is highly dependent on the local concentration of oxygen. The 
intratumoral production of ROS is insufficient since most solid tumors 
are hypoxic, especially the area away from the blood vessels. Therefore, 
the development of O2-independent free radical therapy strategies may 
improve the therapeutic effect by overcoming the hypoxic condition. A 
feasible method to solve the above problems is delivering free radical- 
Fig. 10. (a) The antitumor mechanism of Fe(CO)5@Au under laser irradiation. Reprinted with permission [138]. Copyright 2020, American Chemical Society. (b) 
The photoreduction mechanism of PPOSD and the chemotherapeutic effect of DOX. Reprinted with permission [139]. Copyright 2019, American Chemical Society. 
(c) The synthetic procedure of MCM@PEG–CO–DOX for antitumor therapy. Reprinted with permission [140]. Copyright 2019, Elsevier. (d) Synthetic schematic of 
PPPPB-CO-TPZ NPs for antitumor therapy upon laser irradiation. Reprinted with permission [137]. Copyright 2019, Elsevier. 
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generating precursors to the tumor sites that can be activated via 
external stimulation. A recent study showed that 2,2′-azobis[2-(2-imi-
dazolin-2-yl)propane]dihydrochloride (AIPH) as a conventional poly-
merization initiator can produce alkyl radicals under heat or irradiation 
activation. The generated free radicals can directly oxidize intracellular 
components in hypoxia conditions or react with O2 to produce O2-con-
taining free radicals, such as alkoxy and peroxy groups in a normoxia 
microenvironment [144]. AIPH may become an effective biomedical 
candidate for treating hypoxia tumors. 
To achieve tumor-targeted delivery of AIPH, Xia et al. designed a 
novel nanotherapeutic by integrating AuNC, phase change material 
(PCM), and AIPH into one single nanoplatform (Fig. 11a) [6]. They used 
AuNC to load AIPH and wrapped the surface of AuNC with a PCM outer 
layer. Upon 808 nm laser irradiation, AuNC induced hyperthermia effect 
for inducing phase transition of PCM and then triggering on-demand 
AIPH release. As an azo compound, AIPH decomposed rapidly under 
the stimulation of photothermal-induced heat to generate alkyl radicals. 
These free radicals directly oxidized cellular components or reacted with 
oxygen to generate secondary cytotoxic free radicals, including alkoxy 
and peroxy groups. Even under hypoxic conditions, 
photothermal-induced heat could still induce AIPH to produce free 
radicals to increase intracellular lipid hydroperoxide and ultimately lead 
to oxidation-mediated damage and cell apoptosis. In vitro, experimental 
results showed that the Au-PCM-AIPH in the hypoxia group and the 
normoxia group showed an approximate inhibition rate on A549 cells at 
61.1% and 62.3%, respectively. The experimental data indicated that 
the tumor suppression effect of Au-PCM-AIPH was independent of the 
oxygen level. This novel AIPH-based therapeutic strategy expanded the 
range of reactive species and extended the biomedicine application of 
reactive species-based nanomaterials. 
Lin et al. further prepared a kind of NPs by combining BSA-coated 
magnetic Fe5C2, AIPH, and PCM (Fig. 11b) [145]. This nanoplatform 
exhibited a remarkable cancer cell inhibition effect by producing toxic 
free radicals induced by the photothermal effect. The multifunctional 
therapeutic nanoplatform also combined magnetic targeting function to 
remotely control drug delivery. This study combining the alkyl 
radicles-mediated cancer therapy and the magnetic resonance imaging 
(MRI) performance could realize the MRI-guided antitumor therapy. 
Furthermore, Lin et al. used self-assembly strategies to develop a 
therapeutic platform based on CuFeSe2 NPs, BSA, and AIPH (Fig. 11c) 
[146]. Owing to the strong absorption in the NIR-I and NIR-II spectral 
regions, the CuFeSe2 NPs could activate the release of alkyl radicals and 
exert a favorable inhibition effect at deep-seated tumor tissues. This 
work optimized the penetration effect of the photoactivatable nano-
materials and extended the bio-application of reactive species to the 
deep-seated tumor. Similarly, Qu et al. constructed a theranostic plat-
form by combining AIPH, PCM, and the photoabsorbent PEG-MoS2 
[147]. The designed system could also induce the generation of free 
radicals under NIR laser irradiation. Results suggested that the 
MoS2@AIPH-PCM nanosystem was capable of oxidizing and scavenging 
GSH inside the tumor cells, thus enhancing the therapeutic effect of alkyl 
free radicals. This work explored the mechanism of the influence of alkyl 
radicles on intracellular reducing substances for enhanced antitumor 
effect. 
Organic biomaterials with intrinsic biodegradability have been 
extensively studied and employed as photothermal inducing agents. For 
Fig. 11. (a) The reaction mechanism of photo-triggered generation of alkyl radical species. Reproduced with permission [6]. Copyright 2017, Wiley-VCH. (b) The 
synthetic procedure of Fe5C2-BSA-AIPH/PCM for imaging-guided cancer treatment. Reprinted with permission [145]. Copyright 2018, American Chemical Society. 
(c) Schematic illustration of CuFeSe2-based multifunctional nanomaterials for oxygen-independent synergistic therapy of cancer. Reprinted with permission [146]. 
Copyright 2019, American Chemical Society. (d) The formulation of TPP-NN NPs and the mechanism of 638 nm laser-triggered generation of alkyl radical species for 
antitumor therapy. Reprinted with permission [148]. Copyright 2019, American Chemical Society. 
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example, Xie et al. use Pluronic F-127 to encapsulate a conjugate be-
tween porphyrin and AIPH to form the TPP-NN NPs (Fig. 11d) [148]. 
Under 638 nm laser irradiation, the photothermal effect of porphyrin 
was transferred to AIPH and induced the generation of alkyl radicals. 
The generated alkyl radicals could be detected by monitoring the 
absorbance intensity changes of 1,3-diphenylisobenzofuran in DMF and 
the enhanced fluorescence from 2′,7′-dichlorodihydrofluorescein in 
vitro. In vivo tests indicated that TPP-NN NPs could effectively inhibit 
tumor growth by producing elevated oxidative stress. These results 
demonstrated the excellent treatment efficacy of alkyl radicals-based 
reactive species to cancer cells. The work affirmed that the reactive 
species-based therapeutic strategies have great potential and are 
necessary to be further vigorously developed. 
5. Conclusions and perspectives 
In short, this review first discussed the recent development of ROS- 
based phototherapeutic nanoplatforms for phototherapy and also sum-
marized the advantages or disadvantages of these various nanoplat-
forms. The photochemical mechanism and materials optimization 
approaches are introduced in detail for enhanced therapeutic efficacy to 
tumor cells. Second, the auxiliary functions of ●NO to various kinds of 
therapeutic modalities have been described, which laid the foundation 
of corresponding synergistic interaction in multifunctional nano-
materials. Third, the in-depth bioapplication mechanism of CO- 
containing nanoplatforms has been investigated, which holds much 
promise for the discovery and rational design of precision medicine. 
Subsequently, the reaction mechanism of photo-triggered generation of 
alkyl radical species was discussed, which provided innovative direction 
for biomedical nanomaterials design. 
With the rapid development of nanobiotechnology, reactive species- 
based theranostic has achieved remarkable advances over the past de-
cades [149,150]. Owing to the high controllability and low invasiveness 
of laser irradiation, photoactivatable nanogenerators have been exten-
sively explored for reactive species-based cancer therapy [123]. 
Although several reactive species-generating photosensitive drugs have 
been used clinically, they have not been selected as the first-line treat-
ment due to their intrinsic limitations [35]. The clinically approved 
reactive species-generators are all oxygen-based photosensitive nano-
drugs (5-ALA, Verteporfin, and Porfimer Sodium), and few clinical 
research data on nitrogen and carbon-based reactive species have been 
collected. The oxygen-dependence nature of ROS would be doomed to 
fail to exert ideal therapeutic effects on solid hypoxia tumors. Moreover, 
the absorption wavelengths of most PSs are below 680 nm. The photo 
source with a wavelength below 680 nm is difficult to penetrate the deep 
tumor and activate the PSs distributed inside the tumor tissue [24]. The 
clinical application of photoactivatable radical species is currently 
focused on melanoma, lung cancer, and esophageal cancer [96]. For 
●NO treatment strategies, when nitro is used as a ●NO donor, ultraviolet 
photo source and long-term laser irradiation limit its clinical translation, 
which required designing more optimized donors to meet the standard 
of clinical nanomedicine for efficient cancer therapy. For CO treatment, 
highly tumor-specific delivery of the CO precursor is essential due to 
strong adhesion between CO and hemoglobin. 
Several strategies might be practical to address the above challenges. 
First, we need to pay more attention to study the therapeutic effects of 
photoactivatable reactive species, including attempts to treat the in situ 
tumors and metastatic tumors, as well as injection treatments from mice 
to larger animals, and systematically evaluating their biological distri-
bution, comprehensive pharmacokinetic pharmacodynamics pathway 
and other clinical trials, to obtain more useful clinical data. Second, PDT 
with type I mechanisms should be focused on for treating malignant 
hypoxic tumors. Oxygen self-supplying drug systems or combining with 
hypoxia-activated drugs, such as TPZ should be developed. Third, up- 
conversion materials and two-photon absorption materials could be 
employed to solve the limitation of light wavelength. Also, the photon 
absorption capacity can be enhanced by rational molecular chemical 
designs, and the molecular structure could be smartly designed with 
high intersystem crossing efficiency from the excited state to the excited 
triplet state. Furthermore, synergistic therapy methods may endow 
effective therapeutic effects when the therapeutic outcomes of reactive 
species based on oxygen, nitrogen, and carbon are ineffective. Notably, 
due to the huge advantage of immunotherapy in individualized treat-
ment, we must vigorously explore the immunoregulatory potential of 
reactive species-based nanomedicines [151–154]. Given the safety is-
sues of ●NO and CO, it is a prerequisite to constructing 
nano-pharmaceutical systems with a more precisely controlled release 
profile. Besides, imaging detection strategies based on different reactive 
species can help qualitatively and quantitatively monitor the reactive 
species’ biodistribution and corresponding redox state, thus precisely 
controlling their beneficial treatment and relieving the systemic side 
effects [155–157]. 
It is noted that biosafety is a major concern for developing nano-
therapeutics. The reactive species-generators comprise a diverse range 
of photoactivable nanomaterials or nanoparticles. The nano-
formulations need to be thoroughly optimized [158]. The sense of 
biosafety and biocompatibility is crucial for developing radical 
species-based nanomedicine [159–165]. Multiple discipline collabora-
tion, in particularly the integration of nanotechnology with medicinal 
chemistry and pharmaceutical technology is important to promote the 
clinical translation of the photoactivatable nanomedicine for reactive 
species-based cancer therapy. 
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Cid, S.B. Gómez, J. Blanco, D. Ramaiah, In vitro and in vivo demonstration of 
photodynamic activity and cytoplasm imaging through tpe nanoparticles, ACS 
Chem. Biol. 11 (2016) 104–112. 
[86] G. Jin, G. Feng, W. Qin, B.Z. Tang, B. Liu, K. Li, Multifunctional organic 
nanoparticles with aggregation-induced emission (aie) characteristics for targeted 
photodynamic therapy and rna interference therapy, Chem. Commun. 52 (2016) 
2752–2755. 
[87] Q. Li, Y. Li, T. Min, J. Gong, L. Du, D.L. Phillips, J. Liu, J.W.Y. Lam, H.H.Y. Sung, 
I.D. Williams, R.T.K. Kwok, C.L. Ho, K. Li, J. Wang, B.Z. Tang, Time-dependent 
photodynamic therapy for multiple targets: a highly efficient aie-active 
photosensitizer for selective bacterial elimination and cancer cell ablation, 
Angew. Chem. Int. Ed. 59 (2020) 9470–9477. 
[88] Q. Wan, R. Zhang, Z. Zhuang, Y. Li, Y. Huang, Z. Wang, W. Zhang, J. Hou, B. 
Z. Tang, Molecular engineering to boost aie-active free radical photogenerators 
and enable high-performance photodynamic therapy under hypoxia, Adv. Funct. 
Mater. 30 (2020) 2002057. 
[89] W. Xiong, L. Wang, X. Chen, H. Tang, D. Cao, G. Zhang, W. Chen, Pyridinium- 
substituted tetraphenylethylene salt-based photosensitizers by varying counter 
anions: a highly efficient photodynamic therapy for cancer cell ablation and 
bacterial inactivation, J. Mater. Chem. B 8 (2020) 5234–5244. 
[90] Y. Yuan, C.-J. Zhang, S. Xu, B. Liu, A self-reporting aie probe with a built-in 
singlet oxygen sensor for targeted photodynamic ablation of cancer cells, Chem. 
Sci. 7 (2016) 1862–1866. 
[91] S. Li, Q. Zou, Y. Li, C. Yuan, R. Xing, X. Yan, Smart peptide-based supramolecular 
photodynamic metallo-nanodrugs designed by multicomponent coordination self- 
assembly, J. Am. Chem. Soc. 140 (2018) 10794–10802. 
[92] B. Sun, R. Chang, S. Cao, C. Yuan, L. Zhao, H. Yang, J. Li, X. Yan, J.C.M. van Hest, 
Acid-activatable transmorphic peptide-based nanomaterials for photodynamic 
therapy, Angew. Chem. Int. Ed. 59 (2020) 20582–20588. 
[93] Y. Cai, D. Ni, W. Cheng, C. Ji, Y. Wang, K. Müllen, Z. Su, Y. Liu, C. Chen, M. Yin, 
Enzyme-triggered disassembly of perylene monoimide-based nanoclusters for 
activatable and deep photodynamic therapy, Angew. Chem. Int. Ed. 59 (2020) 
14014–14018. 
[94] M. Li, S. Long, Y. Kang, L. Guo, J. Wang, J. Fan, J. Du, X. Peng, De novo design of 
phototheranostic sensitizers based on structure-inherent targeting for enhanced 
cancer ablation, J. Am. Chem. Soc. 140 (2018) 15820–15826. 
[95] C. He, D. Liu, W. Lin, Nanomedicine applications of hybrid nanomaterials built 
from metal-ligand coordination bonds: nanoscale metal-organic frameworks and 
nanoscale coordination polymers, Chem. Rev. 115 (2015) 11079–11108. 
[96] M. Lismont, L. Dreesen, S. Wuttke, Metal-organic framework nanoparticles in 
photodynamic therapy: current status and perspectives, Adv. Funct. Mater. 27 
(2017) 1606314. 
[97] J. Lu, L. Yang, W. Zhang, P. Li, X. Gao, W. Zhang, H. Wang, B. Tang, 
Photodynamic therapy for hypoxic solid tumors via mn-mof as a photosensitizer, 
Chem. Commun. 55 (2019) 10792–10795. 
[98] T. Luo, K. Ni, A. Culbert, G. Lan, Z. Li, X. Jiang, M. Kaufmann, W. Lin, Nanoscale 
metal-organic frameworks stabilize bacteriochlorins for type i and type ii 
photodynamic therapy, J. Am. Chem. Soc. 142 (2020) 7334–7339. 
[99] G. Lan, Z. Li, S.S. Veroneau, Y.-Y. Zhu, Z. Xu, C. Wang, W. Lin, Photosensitizing 
metal-organic layers for efficient sunlight-driven carbon dioxide reduction, J. Am. 
Chem. Soc. 140 (2018) 12369–12373. 
[100] Z. Yang, W. Fan, J. Zou, W. Tang, L. Li, L. He, Z. Shen, Z. Wang, O. Jacobson, M. 
A. Aronova, P. Rong, J. Song, W. Wang, X. Chen, Precision cancer theranostic 
platform by in situ polymerization in perylene diimide-hybridized hollow 
mesoporous organosilica nanoparticles, J. Am. Chem. Soc. 141 (2019) 
14687–14698. 
[101] H.-T. Feng, Y. Li, X. Duan, X. Wang, C. Qi, J.W.Y. Lam, D. Ding, B.Z. Tang, 
Substitution activated precise phototheranostics through supramolecular 
assembly of aiegen and calixarene, J. Am. Chem. Soc. 142 (2020) 15966–15974. 
[102] L.D. Elliott, S. Kayal, M.W. George, K. Booker-Milburn, Rational design of triplet 
sensitizers for the transfer of excited state photochemistry from uv to visible, 
J. Am. Chem. Soc. 142 (2020) 14947–14956. 
[103] M. Kang, C. Zhou, S. Wu, B. Yu, Z. Zhang, N. Song, M.M.S. Lee, W. Xu, F.-J. Xu, 
D. Wang, L. Wang, B.Z. Tang, Evaluation of structure-function relationships of 
aggregation-induced emission luminogens for simultaneous dual applications of 
specific discrimination and efficient photodynamic killing of gram-positive 
bacteria, J. Am. Chem. Soc. 141 (2019) 16781–16789. 
[104] L. He, Q. Ni, J. Mu, W. Fan, L. Liu, Z. Wang, L. Li, W. Tang, Y. Liu, Y. Cheng, 
L. Tang, Z. Yang, Y. Liu, J. Zou, W. Yang, O. Jacobson, F. Zhang, P. Huang, 
X. Chen, Solvent-assisted self-assembly of a metal-organic framework based 
biocatalyst for cascade reaction driven photodynamic therapy, J. Am. Chem. Soc. 
142 (2020) 6822–6832. 
[105] S. Li, K. Gu, H. Wang, B. Xu, H. Li, X. Shi, Z. Huang, H. Liu, Degradable holey 
palladium nanosheets with highly active 1d nanoholes for synergetic 
phototherapy of hypoxic tumors, J. Am. Chem. Soc. 142 (2020) 5649–5656. 
[106] Y. Jiang, J. Li, Z. Zeng, C. Xie, Y. Lyu, K. Pu, Organic photodynamic nanoinhibitor 
for synergistic cancer therapy, Angew. Chem. Int. Ed. 58 (2019) 8161–8165. 
[107] D. Cui, J. Huang, X. Zhen, J. Li, Y. Jiang, K. Pu, A semiconducting polymer nano- 
prodrug for hypoxia-activated photodynamic cancer therapy, Angew. Chem. Int. 
Ed. 58 (2019) 5920–5924. 
[108] X. Li, D. Lee, J.-D. Huang, J. Yoon, Phthalocyanine-assembled nanodots as 
photosensitizers for highly efficient typei photoreactions in photodynamic 
therapy, Angew. Chem. Int. Ed. 57 (2018) 9885–9890. 
[109] V. Novohradsky, A. Rovira, C. Hally, A. Galindo, G. Vigueras, A. Gandioso, 
M. Svitelova, R. Bresolí-Obach, H. Kostrhunova, L. Markova, J. Kasparkova, 
S. Nonell, J. Ruiz, V. Brabec, V. Marchán, Towards novel photodynamic 
anticancer agents generating superoxide anion radicals: a cyclometalated iriii 
complex conjugated to a far-red emitting coumarin, Angew. Chem. Int. Ed. 58 
(2019) 6311–6315. 
[110] L. Zhang, S. Wang, Y. Zhou, C. Wang, X.-Z. Zhang, H. Deng, Covalent organic 
frameworks as favorable constructs for photodynamic therapy, Angew. Chem. Int. 
Ed. 58 (2019) 14213–14218. 
[111] M. Li, J. Xia, R. Tian, J. Wang, J. Fan, J. Du, S. Long, X. Song, J.W. Foley, X. Peng, 
Near-infrared light-initiated molecular superoxide radical generator: rejuvenating 
photodynamic therapy against hypoxic tumors, J. Am. Chem. Soc. 140 (2018) 
14851–14859. 
[112] M. Li, Y. Shao, J.H. Kim, Z. Pu, X. Zhao, H. Huang, T. Xiong, Y. Kang, G. Li, 
K. Shao, J. Fan, J.W. Foley, J.S. Kim, X. Peng, Unimolecular photodynamic o2- 
economizer to overcome hypoxia resistance in phototherapeutics, J. Am. Chem. 
Soc. 142 (2020) 5380–5388. 
[113] G. Lan, K. Ni, S.S. Veroneau, X. Feng, G.T. Nash, T. Luo, Z. Xu, W. Lin, Titanium- 
based nanoscale metal-organic framework for type i photodynamic therapy, 
J. Am. Chem. Soc. 141 (2019) 4204–4208. 
[114] K. Wang, Z. Zhang, L. Lin, J. Chen, K. Hao, H. Tian, X. Chen, Covalent organic 
nanosheets integrated heterojunction with two strategies to overcome hypoxic- 
tumor photodynamic therapy, Chem. Mater. 31 (2019) 3313–3323. 
[115] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen 
species: role in inflammatory disease and progression to cancer, Biochem. J. 313 
(1996) 17–29. 
[116] M. Valko, C.J. Rhodes, J. Moncol, M. Izakovic, M. Mazur, Free radicals, metals 
and antioxidants in oxidative stress-induced cancer, Chem. Biol. Interact. 160 
(2006) 1–40. 
[117] I. Liguori, G. Russo, F. Curcio, G. Bulli, L. Aran, D. Della-Morte, G. Gargiulo, 
G. Testa, F. Cacciatore, D. Bonaduce, P. Abete, Oxidative stress, aging, and 
diseases, Clin. Interv. Aging 13 (2018) 757–772. 
X. Zheng et al.                                                                                                                                                                                                                                   
Bioactive Materials 6 (2021) 4301–4318
4318
[118] J.M. Fukuto, L.J. Ignarro, In vivo aspects of nitric oxide (no) chemistry: Does 
peroxynitrite (-oono) play a major role in cytotoxicity? Acc. Chem. Res. 30 (1997) 
149–152. 
[119] T. Yang, Z. Du, H. Qiu, P. Gao, X. Zhao, H. Wang, Q. Tu, K. Xiong, N. Huang, 
Z. Yang, From surface to bulk modification: plasma polymerization of amine- 
bearing coating by synergic strategy of biomolecule grafting and nitric oxide 
loading, Bioact. Mater. 5 (2020) 17–25. 
[120] X. Zhang, J. Du, Z. Guo, J. Yu, Q. Gao, W. Yin, S. Zhu, Z. Gu, Y. Zhao, Efficient 
near infrared light triggered nitric oxide release nanocomposites for sensitizing 
mild photothermal therapy, Adv. Sci. 6 (2019) 1801122. 
[121] A.W. Girotti, Nitric oxide-mediated resistance to antitumor photodynamic 
therapy, Photochem. Photobiol. 96 (2020) 500–505. 
[122] Y. Wang, X. Huang, Y. Tang, J. Zou, P. Wang, Y. Zhang, W. Si, W. Huang, X. Dong, 
A light-induced nitric oxide controllable release nano-platform based on 
diketopyrrolopyrrole derivatives for ph-responsive photodynamic/photothermal 
synergistic cancer therapy, Chem. Sci. 9 (2018) 8103–8109. 
[123] C. Fowley, A.P. McHale, B. McCaughan, A. Fraix, S. Sortino, J.F. Callan, Carbon 
quantum dot–no photoreleaser nanohybrids for two-photon phototherapy of 
hypoxic tumors, Chem. Commun. 51 (2015) 81–84. 
[124] J.V. Garcia, J. Yang, D. Shen, C. Yao, X. Li, R. Wang, G.D. Stucky, D. Zhao, P. 
C. Ford, F. Zhang, Nir-triggered release of caged nitric oxide using upconverting 
nanostructured materials, Small 8 (2012) 3800–3805. 
[125] Y. Cao, M. Liu, J. Cheng, J. Yin, C. Huang, H. Cui, X. Zhang, G. Zhao, Acidity- 
triggered tumor-targeted nanosystem for synergistic therapy via a cascade of ros 
generation and no release, ACS Appl. Mater. Interfaces 12 (2020) 28975–28984. 
[126] P.G. Wang, M. Xian, X. Tang, X. Wu, Z. Wen, T. Cai, A.J. Janczuk, Nitric oxide 
donors: Chemical activities and biological applications, Chem. Rev. 102 (2002) 
1091–1134. 
[127] T. Feng, J. Wan, P. Li, H. Ran, H. Chen, Z. Wang, L. Zhang, A novel nir-controlled 
no release of sodium nitroprusside-doped prussian blue nanoparticle for 
synergistic tumor treatment, Biomaterials 214 (2019) 119213. 
[128] S. Pramanick, J. Kim, J. Kim, G. Saravanakumar, D. Park, W.J. Kim, Synthesis and 
characterization of nitric oxide-releasing platinum(iv) prodrug and polymeric 
micelle triggered by light, Bioconjugate Chem. 29 (2018) 885–897. 
[129] X. Zhou, Z. Meng, J. She, Y. Zhang, X. Yi, H. Zhou, J. Zhong, Z. Dong, X. Han, 
M. Chen, Q. Fan, K. Yang, C. Wang, Near-infrared light-responsive nitric oxide 
delivery platform for enhanced radioimmunotherapy, Nano-Micro Lett. 12 (2020) 
100. 
[130] Y. Xu, H. Ren, J. Liu, Y. Wang, Z. Meng, Z. He, W. Miao, G. Chen, X. Li, 
A switchable no-releasing nanomedicine for enhanced cancer therapy and 
inhibition of metastasis, Nanoscale 11 (2019) 5474–5488. 
[131] L. Tan, R. Huang, X. Li, S. Liu, Y.-M. Shen, Controllable release of nitric oxide and 
doxorubicin from engineered nanospheres for synergistic tumor therapy, Acta 
Biomater. 57 (2017) 498–510. 
[132] J. Li, R. Jiang, Q. Wang, X. Li, X. Hu, Y. Yuan, X. Lu, W. Wang, W. Huang, Q. Fan, 
Semiconducting polymer nanotheranostics for nir-ii/photoacoustic imaging- 
guided photothermal initiated nitric oxide/photothermal therapy, Biomaterials 
217 (2019) 119304. 
[133] E.Y. Zhou, H.J. Knox, C.J. Reinhardt, G. Partipilo, M.J. Nilges, J. Chan, Near- 
infrared photoactivatable nitric oxide donors with integrated photoacoustic 
monitoring, J. Am. Chem. Soc. 140 (2018) 11686–11697. 
[134] H. Yan, J. Du, S. Zhu, G. Nie, H. Zhang, Z. Gu, Y. Zhao, Emerging delivery 
strategies of carbon monoxide for therapeutic applications: from co gas to co 
releasing nanomaterials, Small 15 (2019) 1904382. 
[135] L. Chen, S.-F. Zhou, L. Su, J. Song, Gas-mediated cancer bioimaging and therapy, 
ACS Nano 13 (2019) 10887–10917. 
[136] C. Liu, Z. Du, M. Ma, Y. Sun, J. Ren, X. Qu, Carbon monoxide controllable 
targeted gas therapy for synergistic anti-inflammation, iScience 23 (2020) 
101483. 
[137] Y. Li, J. Dang, Q. Liang, L. Yin, Carbon monoxide (co)-strengthened cooperative 
bioreductive anti-tumor therapy via mitochondrial exhaustion and hypoxia 
induction, Biomaterials 209 (2019) 138–151. 
[138] X.-S. Wang, J.-Y. Zeng, M.-J. Li, Q.-R. Li, F. Gao, X.-Z. Zhang, Highly stable iron 
carbonyl complex delivery nanosystem for improving cancer therapy, ACS Nano 
14 (2020) 9848–9860. 
[139] S.-B. Wang, C. Zhang, Z.-X. Chen, J.-J. Ye, S.-Y. Peng, L. Rong, C.-J. Liu, X.- 
Z. Zhang, A versatile carbon monoxide nanogenerator for enhanced tumor 
therapy and anti-inflammation, ACS Nano 13 (2019) 5523–5532. 
[140] J. Yao, Y. Liu, J. Wang, Q. Jiang, D. She, H. Guo, N. Sun, Z. Pang, C. Deng, 
W. Yang, S. Shen, On-demand co release for amplification of chemotherapy by 
mof functionalized magnetic carbon nanoparticles with nir irradiation, 
Biomaterials 195 (2019) 51–62. 
[141] S.-B. Wang, C. Zhang, J.-J. Ye, M.-Z. Zou, C.-J. Liu, X.-Z. Zhang, Near-infrared 
light responsive nanoreactor for simultaneous tumor photothermal therapy and 
carbon monoxide-mediated anti-inflammation, ACS Cent. Sci. 6 (2020) 555–565. 
[142] A. Persidis, Cancer multidrug resistance, Nat. Biotechnol. 17 (1999) 94–95. 
[143] Y. Li, J. Dang, Q. Liang, L. Yin, Thermal-responsive carbon monoxide (co) 
delivery expedites metabolic exhaustion of cancer cells toward reversal of 
chemotherapy resistance, ACS Cent. Sci. 5 (2019) 1044–1058. 
[144] M.C. Krishna, M.W. Dewhirst, H.S. Friedman, J.A. Cook, W. Degraff, A. Samuni, 
A. Russo, J.B. Mitchell, Hyperthermic sensitization by the radical initiator 2,2′- 
azobis (2-amidinopropane) dihydrochloride (aaph). I. In vitro studies, Int. J. 
Hyperther. 10 (1994) 271–281. 
[145] L. Feng, S. Gai, Y. Dai, F. He, C. Sun, P. Yang, R. Lv, N. Niu, G. An, J. Lin, 
Controllable generation of free radicals from multifunctional heat-responsive 
nanoplatform for targeted cancer therapy, Chem. Mater. 30 (2018) 526–539. 
[146] J. Yang, R. Xie, L. Feng, B. Liu, R. Lv, C. Li, S. Gai, F. He, P. Yang, J. Lin, 
Hyperthermia and controllable free radical coenhanced synergistic therapy in 
hypoxia enabled by near-infrared-ii light irradiation, ACS Nano 13 (2019) 
13144–13160. 
[147] S. Wu, X. Liu, J. Ren, X. Qu, Glutathione depletion in a benign manner by mos2- 
based nanoflowers for enhanced hypoxia-irrelevant free-radical-based cancer 
therapy, Small 15 (2019) 1904870. 
[148] R. Xia, X. Zheng, X. Hu, S. Liu, Z. Xie, Photothermal-controlled generation of alkyl 
radical from organic nanoparticles for tumor treatment, ACS Appl. Mater. 
Interfaces 11 (2019) 5782–5790. 
[149] M.-X. Wu, Y.-W. Yang, Metal-organic framework (mof)-based drug/cargo delivery 
and cancer therapy, Adv. Mater. 29 (2017) 1606134. 
[150] W. Cai, J. Wang, C. Chu, W. Chen, C. Wu, G. Liu, Metal-organic framework-based 
stimuli-responsive systems for drug delivery, Adv. Sci. 6 (2019) 1801526. 
[151] B. Feng, B. Hou, Z. Xu, M. Saeed, H. Yu, Y. Li, Self-amplified drug delivery with 
light-inducible nanocargoes to enhance cancer immunotherapy, Adv. Mater. 31 
(2019) 1902960. 
[152] P. Cheng, Q. Miao, J. Li, J. Huang, C. Xie, K. Pu, Unimolecular chemo-fluoro- 
luminescent reporter for crosstalk-free duplex imaging of hepatotoxicity, J. Am. 
Chem. Soc. 141 (2019) 10581–10584. 
[153] J. Li, Y. Luo, K. Pu, Electromagnetic nanomedicines for combinational cancer 
immunotherapy, Angew. Chem. Int. Ed. (2020), https://doi.org/10.1002/ 
anie.202008386. 
[154] Z. Zeng, C. Zhang, J. Li, D. Cui, Y. Jiang, K. Pu, Activatable polymer nanoenzymes 
for photodynamic immunometabolic cancer therapy, Adv. Mater. 33 (2021) 
2007247. 
[155] P. Cheng, J. Zhang, J. Huang, Q. Miao, C. Xu, K. Pu, Near-infrared fluorescence 
probes to detect reactive oxygen species for keloid diagnosis, Chem. Sci. 9 (2018) 
6340–6347. 
[156] J. Huang, J. Huang, P. Cheng, Y. Jiang, K. Pu, Near-infrared chemiluminescent 
reporters for in vivo imaging of reactive oxygen and nitrogen species in kidneys, 
Adv. Funct. Mater. 30 (2020) 2003628. 
[157] J. Huang, J. Li, Y. Lyu, Q. Miao, K. Pu, Molecular optical imaging probes for early 
diagnosis of drug-induced acute kidney injury, Nat. Mater. 18 (2019) 1133–1143. 
[158] R.H.J. Mathijssen, A. Sparreboom, J. Verweij, Determining the optimal dose in 
the development of anticancer agents, Nat. Rev. Clin. Oncol. 11 (2014) 272–281. 
[159] L. Wang, L. Yan, J. Liu, C. Chen, Y. Zhao, Quantification of nanomaterial/ 
nanomedicine trafficking in vivo, Anal. Chem. 90 (2017) 589–614. 
[160] C. Chen, Y.-F. Li, Y. Qu, Z. Chai, Y. Zhao, Advanced nuclear analytical and related 
techniques for the growing challenges in nanotoxicology, Chem. Soc. Rev. 42 
(2013) 8266–8303. 
[161] A.C. Anselmo, S. Mitragotri, Nanoparticles in the clinic, Bioeng. Transl. Med. 1 
(2016) 10–29. 
[162] D. Bobo, K.J. Robinson, J. Islam, K.J. Thurecht, S.R. Corrie, Nanoparticle-based 
medicines: a review of fda-approved materials and clinical trials to date, Pharm. 
Res. (N. Y.) 33 (2016) 2373–2387. 
[163] H. Chen, W. Zhang, G. Zhu, J. Xie, X. Chen, Rethinking cancer nanotheranostics, 
Nat. Rev. Mater. 2 (2017) 17024. 
[164] H. Chen, Z. Gu, H. An, C. Chen, J. Chen, R. Cui, S. Chen, W. Chen, X. Chen, 
X. Chen, Z. Chen, B. Ding, Q. Dong, Q. Fan, T. Fu, D. Hou, Q. Jiang, H. Ke, 
X. Jiang, G. Liu, S. Li, T. Li, Z. Liu, G. Nie, M. Ovais, D. Pang, N. Qiu, Y. Shen, 
H. Tian, C. Wang, H. Wang, Z. Wang, H. Xu, J.-F. Xu, X. Yang, S. Zhu, X. Zheng, 
X. Zhang, Y. Zhao, W. Tan, X. Zhang, Y. Zhao, Precise nanomedicine for 
intelligent therapy of cancer, Sci. China Chem. 61 (2018) 1503–1552. 
[165] J.I. Hare, T. Lammers, M.B. Ashford, S. Puri, G. Storm, S.T. Barry, Challenges and 
strategies in anti-cancer nanomedicine development: an industry perspective, 
Adv. Drug Deliv. Rev. 108 (2017) 25–38. 
X. Zheng et al.                                                                                                                                                                                                                                   
